Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25702747 | 0.81 | CYP1A2 (0.36) | BAZ2BCYP1A2CYP2C19KDM4ENPC1 | |
| SCHEMBL14511472 | 0.77 | BAZ2B (0.44) | BAZ2BCDC7DBF4HDAC8HDAC6 | |
| SCHEMBL8572414 | 0.68 | BAZ2B (0.46) | BAZ2BCDC7DBF4CYP1A2HDAC8 | |
| SCHEMBL2345322 | 0.68 | GSK3B (0.52) | BAZ2BCDC7DBF4HDAC8HDAC6 | |
| SCHEMBL13113437 | 0.68 | MAPT (0.47) | ALDH1A1KDM4EHPGDNPC1SMN1; SMN2 | |
| SCHEMBL4785617 | 0.67 | CYP1A2 (0.46) | CYP1A2CYP2C19ALDH1A1KDM4ENPSR1 | |
| SCHEMBL2062392 | 0.65 | GAA (0.45) | BAZ2BCDC7DBF4HDAC8HDAC6 | |
| SCHEMBL15519348 | 0.65 | BAZ2B (0.44) | BAZ2BCDC7DBF4HDAC8HDAC6 | |
| SCHEMBL13940487 | 0.64 | GAA (0.45) | BAZ2BCDC7DBF4HDAC8HDAC6 | |
| SCHEMBL14511473 | 0.63 | F10 (0.45) | BAZ2BHDAC8HDAC6HDAC2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | SCHERING CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
| US-7964646-B2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-7947720-B2 | 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-05-24 | — | — | US | disclosed |
| US-7786149-B2 | Thiadiazoles as CXC- and CC- chemokine receptor ligands | SCHERING CORP. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7691856-B2 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2010-04-06 | — | — | US | disclosed |
| US-7671212-B2 | Isothiazole dioxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1818325-B1 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORP (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION | 2009-12-10 | — | — | US | disclosed |
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2008-04-17 | — | — | US | disclosed |
| US-7338968-B2 | Thiadiazoles AS CXC- and CC- chemokine receptor ligands | SCHERING CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-7132445-B2 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060223864-A1 | Thiadiazoles AS CXC- and CC- chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2006-10-05 | — | — | US | disclosed |
| US-20060025453-A1 | Isothiazole dioxides as CXC- and CC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY, INC. | 2006-02-02 | — | — | US | disclosed |
| US-20040235908-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists | SCHERING CORPORATION | 2004-11-25 | — | — | US | disclosed |
| US-20040186142-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC- chemokine receptor ligands | SCHERING CORPORATION PHARMACOPEIA, INC. | 2004-09-23 | — | — | US | disclosed |
| US-20040147559-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2004-07-29 | — | — | US | disclosed |
| US-20040106794-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION | 2004-06-03 | — | — | US | disclosed |
| US-20040097547-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | PHARMACOPEIA DRUG DISCOVERY | 2004-05-20 | — | — | US | disclosed |
| US-20030204085-A1 | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists | PHARMACOPEIA, INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030097004-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists | SCHERING CORPORATION | 2003-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235908-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists | CCR1, CXCR1, ACKR3 | BAZ2B 2361/4885CDC7 948/4885DBF4 3443/4885 |
| US-20080090823-A1 | THIADIAZOLES AS CXC- AND CC- CHEMOKINE RECEPTOR LIGANDS | CCR2, ACKR3, CX3CR1 | BAZ2B 1607/4885CDC7 1771/4885DBF4 4418/4885 |
| US-20060025453-A1 | Isothiazole dioxides as CXC- and CC-chemokine receptor ligands | CCR2, CXCR1, CXCR2 | BAZ2B 2520/4885CDC7 1358/4885DBF4 3155/4885 |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | CCR1, ACKR3, CXCR1 | BAZ2B 2347/4885CDC7 1127/4885DBF4 3328/4885 |
| US-20040147559-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, CXCR1, ACKR3 | BAZ2B 2454/4885CDC7 1254/4885DBF4 3654/4885 |
| US-20060223864-A1 | Thiadiazoles AS CXC- and CC- chemokine receptor ligands | CCR2, ACKR3, CX3CR1 | BAZ2B 1607/4885CDC7 1771/4885DBF4 4418/4885 |
| US-20040186142-A1 | Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC- chemokine receptor ligands | CXCR1, CCR2, CX3CR1 | BAZ2B 2088/4885CDC7 1632/4885DBF4 4205/4885 |
| US-20040097547-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, CXCR1, ACKR3 | BAZ2B 2454/4885CDC7 1254/4885DBF4 3654/4885 |
| US-20030097004-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists | CCR1, ACKR3, CXCR1 | BAZ2B 2687/4885CDC7 638/4885DBF4 2901/4885 |
| US-20040106794-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, CXCR1, ACKR3 | BAZ2B 2454/4885CDC7 1254/4885DBF4 3654/4885 |
| US-20030204085-A1 | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists | CCR1, CXCR1, ACKR3 | BAZ2B 2361/4885CDC7 948/4885DBF4 3443/4885 |
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | CCR1, ACKR3, CXCR1 | BAZ2B 2347/4885CDC7 1127/4885DBF4 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.